Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, providing some relief to investors after ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to ...

"We believe this potential new medicine can deliver even ... Tirzepatide, the active ingredient in Eli Lilly's weight loss shot Zepbound and diabetes drug Mounjaro, mimics two of the hormones ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...